Information Provided By: 
Fly News Breaks for April 28, 2015
MDGN
Apr 28, 2015 | 06:03 EDT
Piper Jaffray believes the selloff yesterday in shares of Medgenics, which was part of a broader biotech pullback, provides a "rare" buying opportunity with significant upside. Medgenics has achieved proof-of-concept with the first six patients implanted with MDGN-201 and initiated a Phase II study in peritoneal dialysis patients, Piper notes. The firm views the stock as undervalued and reiterates an Overweight rating on the name with a $15 price target.
News For MDGN From the Last 2 Days
There are no results for your query MDGN
